08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

VTP-34072: Additional Phase II data

Top-line data from the monotherapy arm of the double-blind, German Phase II trial in overweight Type II diabetics showed that once-daily oral VTP-34072 missed the “predefined primary efficacy endpoint criteria” of the change in FPG...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

VTP-34072: Phase II data

Top-line data from a double-blind, German Phase II trial in overweight Type II diabetics showed that once-daily oral VTP-34072 as an add-on to metformin background therapy missed Boehringer’s “predefined endpoint criteria” on the primary efficacy...
07:00 , Jul 13, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , Oct 27, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
02:25 , Sep 25, 2014 |  BC Extra  |  Financial News

Vitae prices IPO below range

Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) was down $0.39 to $7.61 in its first day of trading Wednesday after raising $55 million through the sale of 6.9 million shares at $8 in an IPO on NASDAQ. The...
02:14 , Sep 9, 2014 |  BC Extra  |  Financial News

Vitae sets IPO terms

Vitae Pharmaceuticals Inc. (Fort Washington, Pa.) set the terms for its IPO on NASDAQ. The company plans to sell 5 million shares at $11-$13. At the $12 midpoint, Vitae would raise $60 million and be...
01:34 , Aug 14, 2014 |  BC Extra  |  Financial News

Vitae files for IPO

Vitae Pharmaceuticals Inc. (Fort Washington, Pa.) filed to raise up to $55 million in an IPO on NASDAQ underwritten by Stifel; BMO Capital Markets; JMP Securities; and Wedbush PacGrow. Vitae's lead compound, VTP-34072, is in...